Detalhe da pesquisa
1.
Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic.
BMC Immunol
; 24(1): 2, 2023 01 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36631764
2.
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Haematologica
; 104(5): 955-962, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30514803
3.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Lancet Haematol
; 11(2): e101-e113, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38302221
4.
Curricular course for medical students at a hematology and oncology specialty practice, 2010-2022.
GMS J Med Educ
; 39(4): Doc40, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36310886
5.
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial.
Cancers (Basel)
; 14(3)2022 Jan 20.
Artigo
Inglês
| MEDLINE | ID: mdl-35158789
6.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Lancet Haematol
; 9(11): e810-e821, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-36328040
7.
Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995-2017.
Leuk Lymphoma
; 61(3): 557-566, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31682164
8.
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC.
J Immunother Cancer
; 8(2)2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33199511
9.
Improved survival of patients with metastatic breast cancer in routine care: results of a retrospective study in a community-based oncology group practice 1995-2005.
Onkologie
; 32(3): 107-13, 2009 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-19295249
10.
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Eur J Cancer
; 106: 181-192, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30528802
11.
Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Clin Transl Med
; 14(4): e1617, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38664548
12.
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Leuk Lymphoma
; 48(7): 1299-306, 2007 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-17613757
13.
Ovarian cancer treatment reality in northern Rheinland-Pfalz (Germany). Suboptimal surgical treatment as a possible cause for inferior survival.
Onkologie
; 30(12): 611-7, 2007 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-18063873
14.
Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014.
Oncol Res Treat
; 39(1-2): 41-4, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-26891217
15.
Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice.
Springerplus
; 5: 270, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-27006879
16.
Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors.
Springerplus
; 3: 535, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25279326
17.
Breast cancer morbidity: questionnaire survey of patients on the long term effects of disease and adjuvant therapy.
Dtsch Arztebl Int
; 111(31-32): 537-44, 2014 Aug 04.
Artigo
Inglês
| MEDLINE | ID: mdl-25145512
18.
Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
Leuk Lymphoma
; 54(8): 1640-6, 2013 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-23151046
19.
Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia.
Leuk Lymphoma
; 50(9): 1468-74, 2009 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-21049589